Press Releases
Date Title and Summary View
Jan 29, 2015 SUNNYVALE, Calif., Jan. 29, 2015 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted single-agent IMBRUVICA® (ibrutinib) regular (full) approval in all lines of therapy as the first and only treatment for patients with Waldenstrom's macroglobulinemia (WM), a rare, indo...
Jan 12, 2015 SUNNYVALE, Calif., Jan. 12, 2015 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today provided its preliminary unaudited 2014 U.S. net product revenue results and 2015 U.S. net product revenue outlook at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.  For the fiscal year ended December 31, 2014, U.S. net product revenue...
Jan 5, 2015 SUNNYVALE, Calif., Jan. 5, 2015 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that treatment with single-agent IMBRUVICA® (ibrutinib) in treatment-naive and previously treated patients with chronic lymphocytic leukemia (CLL) resulted in a significant response rate, with 92% of high-risk CLL patients with deletion 17p (del ...
Dec 22, 2014 SUNNYVALE, Calif., Dec. 22, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that the U.S Food and Drug Administration (FDA) has provided a Prescription Drug User Fee Act (PDUFA) target date of April 17, 2015 by which time the FDA is planning to finalize its review of a supplemental New Drug Application (sNDA) for IMBRUVICA (...
Dec 12, 2014 SUNNYVALE, Calif., Dec. 12, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has been awarded BayBio's 2014 Pantheon DiNA™ Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA® (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in...
Dec 9, 2014 SAN FRANCISCO, Dec. 9, 2014 /PRNewswire/ -- New, 27-month IMBRUVICA® (ibrutinib) median follow-up data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma (MCL), an aggressive type of lymphoma. More than 30% of IMBRUVICA patient...
Dec 9, 2014 SAN FRANCISCO, Dec. 9, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced new, longer term data in IMBRUVICA® (ibrutinib) patients with relapsed/refractory chronic lymphocytic leukemia (CLL), including high-risk CLL patients with deletion 17p (del 17p). Results from the Phase III RESONATE™ (PCYC-1112) trial demonstra...
Dec 9, 2014 SAN FRANCISCO, Dec. 9, 2014 /PRNewswire/ -- New IMBRUVICA® (ibrutinib) Phase II data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in...
Dec 8, 2014 SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- New, 27-month IMBRUVICA® (ibrutinib) median follow-up data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma (MCL), an aggressive type of lymphoma. More than 30% of IMBRUVICA patient...
Dec 8, 2014 SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced new, longer term data in IMBRUVICA® (ibrutinib) patients with relapsed/refractory chronic lymphocytic leukemia (CLL), including high-risk CLL patients with deletion 17p (del 17p). Results from the Phase III RESONATE™ (PCYC-1112) trial demonstra...
1
... NextLast
Add to Briefcase = add release to Briefcase